Tag Archives: Targeted protein degradation

Drugging The Undruggable: Kymera’s Targeted Protein Degradation
October 30, 2017

The term “undruggable” has entered common industry vernacular over the past two decades to describe biologic targets that couldn’t be addressed via narrow conventional pharmacologies involving catalytic-site inhibitors and antibodies. The “druggable genome” historically included intracellular catalytic proteins, (e.g., enzymes

Leave a comment